ARVN - Arvinas, Inc.
NEXT EARNINGS:
Apr 29, 2026
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$13.17
DETAILS
HIGH:
$18.00
LOW:
$6.00
MEDIAN:
$14.00
CONSENSUS:
$13.17
UPSIDE:
6.47%
Market Cap:
908.18M
Volume:
1,738,308
Avg Volume:
878,666
52 Week Range:
5.9-18.93
Sector:
Healthcare
Industry:
Biotechnology
Beta:
1.88
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
430
IPO Date:
2018-09-27
EPS (TTM):
-1.28
P/E Ratio:
-9.53
Revenue (TTM):
262.60M
Total Assets:
717.90M
Total Debt:
8.50M
Cash & Equiv:
142.90M
Rev Growth (5Y):
58.9%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
N/A
Debt/Equity:
0.02
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-05 | $-0.48 | $-0.75 | +36.0% | $41.9M | $37.3M | +12.4% |
| 2025-08-06 | $-0.84 | $-0.87 | +3.4% | $22.4M | $25.0M | -10.4% |
| 2025-05-01 | $1.14 | $-0.86 | +232.6% | $188.8M | $42.3M | +346.3% |
| 2025-02-11 | $-0.63 | $-1.07 | +41.1% | $59.2M | $42.5M | +39.2% |
| 2024-10-30 | $-0.68 | $-0.88 | +22.7% | $102.4M | $59.5M | +72.1% |
| 2024-07-30 | $-0.49 | $-0.72 | +31.9% | $76.5M | $54.5M | +40.3% |
| 2024-05-07 | $-0.97 | $-1.48 | +34.5% | $25.3M | $34.8M | -27.4% |
| 2024-02-27 | $-2.53 | $-1.33 | -90.2% | $43.1M | $49.3M | -12.6% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 262.60M | 263.40M | 78.50M | 131.40M | 53.60M | 25.90M | 42.98M | 14.32M | 7.58M | 6.67M |
| Net Income | (80.80M) | (198.90M) | (367.30M) | (282.50M) | (191.00M) | (119.30M) | (70.29M) | (41.48M) | (24.05M) | (14.35M) |
| EPS | -1.28 | -2.77 | -6.62 | -5.31 | -3.82 | -3.02 | -1.89 | -1.31 | -1.38 | -7.56 |
| Total Assets | 717.90M | 1.09B | 1.30B | 1.27B | 1.58B | 717.40M | 301.64M | 199.28M | 66.85M | 37.94M |
| Total Debt | 8.50M | 9.70M | 3.20M | 5.50M | 5.00M | 4.10M | 4.39M | 2.15M | 310,387 | 453,787 |
| Cash & Equivalents | 142.90M | 100.50M | 311.70M | 81.30M | 108.30M | 588.40M | 9.21M | 3.19M | 30.91M | 5.09M |
| Operating Cash Flow | N/A | (259.30M) | (347.80M) | (273.50M) | 559.40M | (89.76M) | (40.63M) | (16.12M) | 5.11M | (19.40M) |
| Free Cash Flow | N/A | (261.10M) | (350.70M) | (280.30M) | 554.70M | (96.20M) | (46.87M) | (18.95M) | 4.10M | (19.71M) |
| FCF per Share | N/A | -3.63 | -6.32 | -5.27 | 11.09 | -2.43 | -1.42 | -0.60 | 0.20 | -10.39 |
| Book Value | 433.90M | 561.70M | 660.00M | 564.90M | 781.70M | 642.20M | 226.69M | 136.67M | 245,870 | 24.03M |
| Cash & ST Investments | 685.40M | 1.04B | 1.26B | 1.21B | 1.50B | 688.60M | 280.87M | 187.83M | 39.17M | 35.56M |
| ROC Equity | -0.19 | -0.35 | -0.56 | -0.50 | -0.24 | -0.19 | -0.31 | -0.30 | -97.81 | -0.60 |